



# Makers Laboratories Ltd.

Regd. Office : 54-D, Kandivli Indl. Estate, Kandivli (West), Mumbai - 400 067.

CIN: L24230MH1984PLC033389, website: [www.makerslabs.com](http://www.makerslabs.com), e-mail: [makers@makerslabs.com](mailto:makers@makerslabs.com)

## THRU ONLINE FILING

August 12, 2020

BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 023

Dear Sir,

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith our Unaudited Financial Results along with limited review report of the Company's Auditors thereon for the 1<sup>st</sup> Quarter ended 30<sup>th</sup> June, 2020, which was taken on record at the Meeting of the Board of Directors of the Company held today at Kandivli, Mumbai.

Kindly note the meeting started at 10.30 a.m. and concluded at 11.30 a.m.

Thanking you

Yours faithfully  
For Makers Laboratories Limited

Khyati Danani  
Company Secretary  
ACS 21844

**Makers Laboratories Limited**

Regd. Office : 54D, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067

CIN : L24230MH1984PLC033389

Tel:+91 22 28688544 E-mail : investors@makerslabs.com , Website : www.makerslabs.com

**STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2020**


(Rs. In Lacs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2020 (Unaudited)	31.03.2020 (Audited)	30.06.2019 (Unaudited)	31.03.2020 (Audited)
I	Revenue from Operations	913.82	1,253.58	1,024.89	5,139.66
II	Other Income	19.36	12.73	4.44	22.55
III	<b>Total Income (I + II)</b>	<b>933.18</b>	<b>1,266.31</b>	<b>1,029.33</b>	<b>5,162.21</b>
IV	<b>Expenses:</b>				
	a) Cost of materials consumed	110.38	151.64	228.51	782.33
	b) Purchases of stock-in-trade	309.62	348.64	215.00	2,098.46
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(22.23)	129.81	145.17	70.14
	d) Employee benefits expense	194.18	199.68	192.55	783.88
	e) Finance Cost	39.56	26.48	6.86	70.31
	f) Depreciation and amortisation expense	100.10	61.94	37.76	198.75
	g) Other expenses	204.71	268.45	257.03	1,133.44
	<b>Total Expenses (IV)</b>	<b>936.32</b>	<b>1,186.64</b>	<b>1,082.88</b>	<b>5,137.31</b>
V	<b>Profit / (Loss) before tax (III - IV)</b>	<b>(3.14)</b>	<b>79.67</b>	<b>(53.55)</b>	<b>24.90</b>
VI	<b>Tax Expense</b>				
	Current Tax	-	3.82	-	3.82
	Deferred Tax (Asset) / Liability	(4.70)	42.61	8.33	33.46
VII	<b>Net Profit / (Loss) after tax (V-VI)</b>	<b>1.56</b>	<b>33.24</b>	<b>(61.88)</b>	<b>(12.38)</b>
VIII	<b>Other Comprehensive Income</b>				
	a) Items that will not be reclassified to profit & loss	289.47	269.13	(67.71)	408.52
	Less: Tax expenses thereon	35.36	27.74	(7.54)	45.08
	<b>Other Comprehensive Income</b>	<b>254.11</b>	<b>241.39</b>	<b>(60.17)</b>	<b>363.44</b>
IX	<b>Total Comprehensive Income after tax (VII + VIII)</b>	<b>255.67</b>	<b>274.63</b>	<b>(122.05)</b>	<b>351.06</b>
X	Paid-up equity share capital (Face value of Rs.10/- each)	491.70	491.70	491.70	491.70
XI	Other Equity				3,970.23
XII	Earnings per share (of Rs.10/- each) - Not annualised:				
	Basic & Diluted	0.03	0.68	(1.26)	(0.25)

**Notes:**


- The above unaudited financial results, as reviewed by the Audit Committee, were approved and taken on record by the Board of Directors in their meeting held on August 12, 2020
- The statutory auditors have carried out a limited review of the financial results and have issued their unmodified report thereon.
- The financial statements are prepared in accordance with the Indian Accounting Standards (Ind-AS) as prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Amendment Rules, 2016.
- Being manufacturers of pharmaceuticals and providers of essential services, the Company is continuing with its manufacturing and marketing operations strictly following the Covid-19 related guidelines issued by the government from time to time. The Company has considered possible impact of Covid-19 on the carrying amounts of property, plant and equipments, investments, inventories, receivables and other current assets. The Company expects that the carrying amounts of the assets are recoverable and that the Company will continue to have sufficient liquidity to finance its business operations as well as expansion plans. However, the Company's business continues to be impacted due to lower patient footfall in dispensaries, nursing homes and hospitals due to Covid-19 pandemic.
- The figures for the quarter ended March 31, 2020 are the balancing figure between the Audited Figures in respect of full financial year and the reviewed year-to-date figures up to the third quarter of the financial year.
- The Company has only one reportable segment viz. 'Pharmaceuticals'.
- Figures for the previous period have been regrouped / re-classified to conform to the figures of the current period.

Place : Mumbai,  
Date : August 12, 2020



By Order of the Board  
For Makers Laboratories Limited

*N. N. Jain*  
Nilesh Jain  
Wholetime Director  
(DIN 05263110)



# *Natvarlal Vepari & Co.*


## CHARTERED ACCOUNTANTS

903-904, 9th Floor, Raheja Chambers, 213, Nariman Point, Mumbai 400 021. Tel. : 6752 7100 Fax : 6752 7101 E-mail : nvc@nvc.in

### REVIEW REPORT

To,  
The Board of Directors  
Makers Laboratories Limited,  
Mumbai.

1. We have reviewed the accompanying statement of unaudited financial results of Makers Laboratories Limited ("the Company") for the quarter ended June 30, 2020 ("the Statement"). This Statement has been prepared by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, as modified by Circular No. CIR / CFD / FAC / 62 / 2016 dated July 5, 2016.
2. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. This statement has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement of unaudited financial results based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatements. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Attention is drawn to the fact that the figures for the 3 months ended March 31, 2020 as reported in these financial results are the balancing figures between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had been subjected to review.



# *Natvarlal Vepari & Co.*

## CHARTERED ACCOUNTANTS

903-904, 9th Floor, Raheja Chambers, 213, Nariman Point, Mumbai 400 021. Tel. : 6752 7100 Fax : 6752 7101 E-mail : nvc@nvc.in

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standards as specified under section 133 of the Companies Act, 2013, read with rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the relevant rules issued thereunder including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Natvarlal Vepari & Co  
Chartered Accountants  
Firm Registration No. 106971W

  
N Jayendran

Partner

M. No. 40441

UDIN: 20040441AAAAAT4081

Mumbai, Dated: - August 12, 2020

